EUVIMEDEUVIMED entdecken
Crossref

PROCEADE\xAE‐CRC‐03: A Phase 3 study of precemtabart tocentecan (Precem‐TcT), as monotherapy or plus bevacizumab, in patients with advanced metastatic colorectal cancer (mCRC)

Asia-Pacific Journal of Clinical Oncology · 2026-11 · 22 (S6) · 19-19

DOI: 10.1111/ajco.70234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 19.11.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). PROCEADE\xAE‐CRC‐03: A Phase 3 study of precemtabart tocentecan (Precem‐TcT), as monotherapy or plus bevacizumab, in patients with advanced metastatic colorectal cancer (mCRC). Asia-Pacific Journal of Clinical Oncology, 22(S6), 19-19. https://doi.org/10.1111/ajco.70234

Vancouver

PROCEADE\xAE‐CRC‐03: A Phase 3 study of precemtabart tocentecan (Precem‐TcT), as monotherapy or plus bevacizumab, in patients with advanced metastatic colorectal cancer (mCRC). Asia-Pacific Journal of Clinical Oncology. 2026;22(S6):19-19. doi:10.1111/ajco.70234

BibTeX
@article{euvimed2026,
  title = {PROCEADE\xAE‐CRC‐03: A Phase 3 study of precemtabart tocentecan (Precem‐TcT), as monotherapy or plus bevacizumab, in patients with advanced metastatic colorectal cancer (mCRC)},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2026},
  volume = {22},
  number = {S6},
  pages = {19--19},
  doi = {10.1111/ajco.70234}
}
Kostenlos starten →